Symlin

Symlin is a brand name of pramlintide, approved by the FDA in the following formulation(s):

SYMLIN (pramlintide acetate - injectable; subcutaneous)

• 
  Manufacturer: AMYLIN
  
  Approval date: March 16, 2005
  
  Strength(s): EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) ^[RLD]


• 
  Manufacturer: AMYLIN
  
  Approval date: September 25, 2007
  
  Strength(s): EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML), EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)
  

Has a generic version of Symlin been approved?

No. There is currently no therapeutically equivalent version of Symlin available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symlin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Amylin agonist peptides and uses therefor
  Patent 5,686,411
  Issued: November 11, 1997
  Inventor(s): Gaeta; Laura S. L. & Jones; Howard & Albrecht; Elisabeth
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
  
  Patent expiration dates:
  
  
  • March 16, 2019
    
    ✓ 
    Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method and composition for treatment of insulin requiring mammals
  Patent 5,814,600
  Issued: September 29, 1998
  Inventor(s): Rink; Timothy J. & Young; Andrew A.
  Assignee(s): Amylin Pharmaceuticals Inc.
  Method and compositions for treating a mammal by administering to that mammal an insulin (having the in vitro activity of stimulating glucose incorporation into glycogen in rat soleus muscle) and an amylin (having the in vitro activity of suppressing glucose incorporation into glycogen in rat soleus muscle) using specific molar ratios of an insulin to an amylin.
  
  Patent expiration dates:
  
  
  • September 29, 2015
    
    ✓ 
    Patent use: TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
  
  
  
  • September 29, 2015
    
    ✓ 
    Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
  
  
  
  • September 29, 2015
    
    ✓ 
    Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
  
  



• 
  Methods for regulating gastrointestinal motility
  Patent 6,114,304
  Issued: September 5, 2000
  Inventor(s): Kolterman; Orville G. & Young; Andrew A. & Rink; Timothy J. & Brown; Kathleen Ann Keiting
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
  
  Patent expiration dates:
  
  
  • September 5, 2017
    
    ✓ 
    Patent use: USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
  
  
  
  • September 5, 2017
    
    ✓ 
    Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
  
  



• 
  Methods for regulating gastrointestinal motility
  Patent 6,608,029
  Issued: August 19, 2003
  Inventor(s): Orville G.; Kolterman & Andrew A.; Young & Timothy J.; Rink & Kathleen Ann; Keating Brown
  Assignee(s): Amylin Pharmaceuticals, Inc.
  Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.
  
  Patent expiration dates:
  
  
  • September 7, 2013
    
    ✓ 
    Patent use: USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
  
  
  
  • September 7, 2013
    
    ✓ 
    Patent use: USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
  
  
  
  • September 7, 2013
    
    ✓ 
    Patent use: TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
  
  

See also...

• Symlin Consumer Information (Drugs.com)
• Symlin Vial Consumer Information (Wolters Kluwer)
• Symlin Consumer Information (Cerner Multum)
• Symlin Advanced Consumer Information (Micromedex)
• Symlin AHFS DI Monographs (ASHP)
• Pramlintide Consumer Information (Wolters Kluwer)
• Pramlintide Vial Consumer Information (Wolters Kluwer)
• Pramlintide Consumer Information (Cerner Multum)
• Pramlintide Subcutaneous Advanced Consumer Information (Micromedex)
• Pramlintide Acetate AHFS DI Monographs (ASHP)